No­vo Nordisk in­vests $2.4B in French fa­cil­i­ty to ad­dress boom­ing GLP-1 de­mand

No­vo Nordisk is spend­ing 16 bil­lion DKK ($2.4 bil­lion) to ex­pand its site in France, which fo­cus­es on mak­ing GLP-1 prod­ucts, among oth­er chron­ic dis­ease treat­ments. Just two days pri­or to this an­nounce­ment, the EMA warned about short­ages for the Dan­ish gi­ant’s type 2 di­a­betes drugs, which in some cas­es are com­plete­ly out of stock.

The ex­pand­ed site is in Chartres, which is an hour and 20 minute dri­ve from Paris. The ex­pan­sion will no­tably boost No­vo’s pro­duc­tion of its GLP-1 drugs by “dou­bling” the site’s foot­print.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER